Day Two Early Sessions

It’s difficult to characterize what is going on with our wine drinking friends in France. Sanofi (NYSE: SNY) who presented this morning is somewhat of an enigma when it comes to diabetes. On the one hand they deserve some credit for not giving up. They could have easily thrown in the towel and given up on diabetes. Yet on the other hand based on what we heard today they haven’t learned anything from past mistakes.Here are just a few examples;

1. In a rare admission of a misstep in the breakout session CEO Olivier Brandicourt admitted the . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.